Deal Tracker · Regions

GCC pharma localization & tech-transfer deals

15 technology transfer / localization deals in the GCC tracked by EPT (2025–2026). Most active: Local Content and Government Procurement Authority, ADCAN Pharma, Mubadala Bio & Tabuk Pharmaceuticals. Latest: Viatris → ADCAN Pharma (Technology transfer / Localization, 11 Nov 2026).

15
deals tracked
8
announced in 2026
—
values undisclosed
100%
localization, the top deal type
  • EPT has tracked 15 GCC pharma localization & tech-transfer deals (2025–2026), 8 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (9), UAE (5), Egypt (2) & United States (2).
  • None of these deals disclosed a value, which is common for licensing and distribution agreements in these markets.
  • The most active companies: Local Content and Government Procurement Authority (5), ADCAN Pharma (3), Mubadala Bio (2) & Tabuk Pharmaceuticals (2).

Countries involved

Saudi Arabia (9) · UAE (5) · Egypt (2) · United States (2) · Germany (1) · Italy (1)

Questions

How many GCC pharma localization & tech-transfer deals has EPT tracked?
15 as of 11 Nov 2026, covering 2025–2026; 8 were announced in 2026. The most recent is Viatris → ADCAN Pharma (Technology transfer / Localization, 11 Nov 2026).
Which companies are most active in GCC pharma localization & tech-transfer deals?
Local Content and Government Procurement Authority (5 deals), ADCAN Pharma (3 deals), Mubadala Bio (2 deals), Tabuk Pharmaceuticals (2 deals).
Which countries appear most in GCC pharma localization & tech-transfer deals?
Saudi Arabia (9), UAE (5), Egypt (2), United States (2), Germany (1), Italy (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)